Lee Scott Golden Sells 795 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) Stock

PTC Therapeutics, Inc. (NASDAQ:PTCT) EVP Lee Scott Golden sold 795 shares of PTC Therapeutics stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $50.10, for a total value of $39,829.50. Following the sale, the executive vice president now directly owns 77,856 shares in the company, valued at $3,900,585.60. This trade represents a 1.01 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Lee Scott Golden also recently made the following trade(s):

• On Tuesday, January 7th, Lee Scott Golden sold 810 shares of PTC Therapeutics stock. The shares were sold at an average price of $45.34, for a total transaction of $36,725.40.

PTC Therapeutics Price Performance

Shares of PTCT stock opened at $50.69 on Friday. The company has a market cap of $3.91 billion, a PE ratio of -8.53 and a beta of 0.62. PTC Therapeutics, Inc. has a 1 year low of $24.00 and a 1 year high of $54.16. The stock’s 50 day simple moving average is $46.67 and its two-hundred day simple moving average is $41.56.

Institutional Trading of PTC Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Smartleaf Asset Management LLC boosted its stake in PTC Therapeutics by 78.7% during the fourth quarter. Smartleaf Asset Management LLC now owns 613 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 270 shares during the period. Sterling Capital Management LLC lifted its holdings in shares of PTC Therapeutics by 424.4% in the 4th quarter. Sterling Capital Management LLC now owns 645 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 522 shares during the last quarter. Venturi Wealth Management LLC bought a new stake in shares of PTC Therapeutics in the 4th quarter worth about $68,000. GF Fund Management CO. LTD. purchased a new position in shares of PTC Therapeutics during the 4th quarter worth about $73,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in PTC Therapeutics during the 4th quarter valued at about $77,000.

Analyst Ratings Changes

PTCT has been the topic of several research analyst reports. The Goldman Sachs Group boosted their target price on shares of PTC Therapeutics from $32.00 to $42.00 and gave the stock a “sell” rating in a report on Wednesday, December 4th. Robert W. Baird boosted their price target on shares of PTC Therapeutics from $52.00 to $70.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 3rd. Cantor Fitzgerald raised their price objective on PTC Therapeutics from $76.00 to $113.00 and gave the company an “overweight” rating in a research report on Monday, February 3rd. Citigroup lifted their target price on PTC Therapeutics from $32.00 to $45.00 and gave the stock a “sell” rating in a report on Wednesday, February 12th. Finally, UBS Group increased their price target on PTC Therapeutics from $47.00 to $71.00 and gave the company a “buy” rating in a research note on Tuesday, December 3rd. Three investment analysts have rated the stock with a sell rating, four have given a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $58.85.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.